Windlas Biotech Ltd Q1 FY2025 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/r67ifiteog4shpq5v5rlxnsi.pdf

Key Takeaways


CDMO Vertical: The Core Growth Engine

Komal Gupta: "we don't want any vertical to be looked at on a quarter-to-quarter level because quarter-to-quarter variations will always remain because of various internal as well as external factors, but we are very excited, we are looking positive momentum there and it is not specific to this quarter. Now it is kind of becoming a habit for us and our investors to see."

Injectable Facility: Costs Now, Revenue Later

Hitesh Windlass: "the idea is to use the initial years to register more and more dossiers in our export markets and then in the later years as those registrations get approval, we'll be able to do a much higher profitability business through exports"

Margins: Absorbing Headwinds, Waiting for Revenue


Capacity & M&A: Building for ₹1,000 Cr

Hitesh Windlass: "we are not targeting a size. For us, the idea is to add to the breadth of our business, which can serve all three verticals. So, the quality of the asset is the most important thing and how much can we grow if we acquire that asset"

Trade Generics, Institutional & Exports


European Market Authorizations: The Export Bridge


Guidance & Commitments

CommitmentSpecificsTimeline
Injectable revenue startFirst revenue from sale of stability batchesMid-Q3 FY25, bulk in Q4 FY25
Plant 2 expansion availabilityAdditional capacity onlineEnd of Q2 or beginning of Q3 FY25
Capacity readiness for ₹1,000 Cr revenuePlant expansion plus facility acquisition to remove capacity constraintBy end of FY25
Facility acquisition updateShortlisted facility, documentation not complete; update expectedBy end of next quarter (Q2 FY25)
Margin improvementPositive impact on profitability margins expectedUpon initiation of injectable revenue
Injectable facility export-driven ROCE improvementExports become the driver of profitability and ROCENext 3–4 years
Tax rateMore or less similar tax rate going forwardOngoing
Balance sheet numbers (net cash, working capital)Will be providedBy end of Q2 FY25 (September)

Key Metrics

MetricQ1 FY25
Revenue₹175 cr, +21% YoY
EBITDA₹21 cr, +22% YoY
EBITDA margin12%, overall; existing business margins improved YoY, QoQ, and vs full year FY24
PBT₹18 cr, +12.1% YoY
PBT margin10.5%
EPS₹6.47, +12% YoY from ₹5.79 in Q1 FY24
CDMO revenue₹135.9 cr, +23% YoY; largest ever quarter for the vertical
Trade generics & institutional revenue₹35.1 cr, +14% YoY
Exports revenue₹4.1 cr, +10% YoY
CDMO capacity utilization~65% (excluding injectable plant); peak utilization is 65–70%
Depreciation₹6 cr quarterly run rate, up from ₹3.5 cr; annual depreciation ~₹12 cr
Injectable facility revenue startMid-Q3 FY25 expected first revenue; commercial batches under stability testing
Injectable facility capex₹74–75 cr
Maintenance capex₹10–12 cr per year